Is Ibuprofen Good for Arthritis? Risks and Benefits

Ibuprofen reliably reduces arthritis pain and inflammation, but whether it is “good” for arthritis depends heavily on how long you take it, what dose you use, and what other health conditions you bring to the table. In head-to-head trials it outperforms acetaminophen for joint stiffness and physical function, and it has been a mainstay of both osteoarthritis and rheumatoid arthritis treatment for decades. The catch is a well-documented set of risks to the stomach, kidneys, and cardiovascular system that grow with prolonged use, making the risk-benefit math different for a 35-year-old with mild knee pain than for a 70-year-old on blood pressure medication.

How Well Does Ibuprofen Work for Osteoarthritis?

Osteoarthritis is the most common reason people reach for ibuprofen, and the evidence that it helps is solid. A randomized trial comparing a full anti-inflammatory dose of ibuprofen, a lower analgesic dose, and acetaminophen found that all three improved knee-pain scores, with no dramatic difference between them in most measures.¹ That result sometimes gets cited as evidence that acetaminophen works just as well, but other trials tell a more nuanced story. The IPSO study, which specifically tracked stiffness and physical function in hip and knee osteoarthritis, found that ibuprofen produced significantly greater improvement than acetaminophen across all three subscales measured over two weeks.²

For people whose arthritis involves noticeable inflammation, swelling, or morning stiffness, this makes sense. Ibuprofen works by blocking the enzymes that produce prostaglandins, which are chemicals that drive both pain and inflammation. Acetaminophen handles the pain side but doesn’t do much for inflammation, so it tends to fall short when swelling and stiffness are significant parts of the picture. A randomized trial comparing celecoxib, ibuprofen, and placebo confirmed that both active drugs meaningfully improved total WOMAC scores compared to placebo, with celecoxib and ibuprofen performing roughly equally.³

Ibuprofen for Rheumatoid Arthritis

Rheumatoid arthritis is a different disease from osteoarthritis, driven by the immune system attacking joint tissue rather than by wear and tear. Ibuprofen still has a role, though it is typically used alongside disease-modifying drugs rather than as a standalone treatment. At doses of 1,200 mg per day or more, ibuprofen has been shown to be as effective as aspirin and other NSAIDs for symptom control in rheumatoid arthritis, with better tolerability and safety than aspirin.⁴ It doesn’t slow the underlying disease process, so if you have RA, ibuprofen is there to make your joints hurt less while your other medications work on the root cause.

The Stomach Problem

The most familiar risk of ibuprofen is damage to the gastrointestinal tract. NSAIDs as a class roughly quadruple to fivefold the risk of upper gastrointestinal bleeding and perforation. A large case-control study found an adjusted relative risk of about 4.7 for current NSAID users, and ibuprofen’s individual risk was in the same range as other commonly used NSAIDs like naproxen and diclofenac.⁵

One question people naturally ask is whether the risk fades if you take ibuprofen for months. A systematic review of long-term NSAID use found that when data from randomized trials were pooled, there was a small decline in the yearly GI event rate over time, but cohort studies showed no significant change. The review concluded that precautionary measures should be considered for anyone needing NSAID therapy beyond six months.⁶ In other words, you shouldn’t assume you’re in the clear just because you’ve been fine for the first few months.

Cardiovascular Risks

The cardiovascular picture is more complicated and, for many people, more worrying than the GI risks. The PRECISION trial, the largest randomized study to compare cardiovascular safety across NSAIDs in arthritis patients, found that a primary cardiovascular event occurred in about 2.7% of the ibuprofen group, compared with 2.5% for naproxen and 2.3% for celecoxib.⁷ The differences were small enough that celecoxib was declared noninferior to both, but ibuprofen did sit at the higher end. An analysis of the EudraVigilance adverse-event database found that hypertension was reported more frequently with ibuprofen than with aspirin, and thrombosis reports were higher relative to ketoprofen.⁸

These numbers shouldn’t cause panic in otherwise healthy people using ibuprofen occasionally, but they matter a great deal for people who already have heart disease or who take ibuprofen at prescription doses for months or years. The cardiovascular risk is dose-dependent and duration-dependent, so the lowest effective dose for the shortest time is the standard clinical mantra for good reason.

How Ibuprofen Affects the Kidneys

Your kidneys rely on prostaglandins to maintain adequate blood flow, and since ibuprofen suppresses prostaglandin production, it can reduce renal perfusion. In most healthy people this doesn’t cause noticeable harm, but in people who are already dehydrated, have chronic kidney disease, or take other drugs that stress the kidneys, ibuprofen can tip the balance toward acute kidney injury.⁹

Case reports have documented acute, reversible renal failure with ibuprofen even in patients without obvious predisposing conditions. One published case showed interstitial nephritis with inflammatory cell infiltrates on biopsy, which resolved after discontinuing ibuprofen and initiating steroid therapy, with kidney function returning to normal.¹⁰ The good news is that ibuprofen-related kidney damage is usually reversible once the drug is stopped. The bad news is that people don’t always realize their kidneys are struggling until blood work catches it.

Renal risk was also quantified in the PRECISION trial, where clinically significant kidney events occurred in about 1.1% of ibuprofen users compared with roughly 0.7% for celecoxib and 0.9% for naproxen, a statistically significant difference favoring celecoxib over ibuprofen.¹¹

How Ibuprofen Compares to Acetaminophen

If you have arthritis and are weighing your options, the ibuprofen-versus-acetaminophen question usually comes up first. A Cochrane review of randomized trials concluded that acetaminophen was less effective than NSAIDs for pain reduction, global assessments, and functional status improvements in osteoarthritis. Patients on NSAIDs were more likely to experience a GI side effect, with about 19% reporting one compared to 13% on acetaminophen, though the median trial duration was only six weeks, making it hard to draw long-term safety conclusions from those numbers alone.¹²

A separate meta-analysis confirmed the pattern: NSAIDs produced modestly but significantly better pain scores than acetaminophen, both at rest and during walking.¹³ The practical upshot is that acetaminophen is gentler on the stomach and kidneys, so it remains a reasonable first-line option for mild pain without much inflammation. But once stiffness, swelling, or moderate-to-severe pain enters the picture, ibuprofen’s anti-inflammatory muscle becomes clinically meaningful.

How Ibuprofen Stacks Up Against Other NSAIDs

People who’ve been told to take an NSAID often want to know whether ibuprofen is the best pick or whether naproxen or celecoxib would be smarter. A secondary analysis of the PRECISION trial looked at overall major toxicity, combining cardiovascular, GI, and renal events. The ibuprofen arm had the highest overall rate at about 5.3%, compared with 4.8% for naproxen and 4.1% for celecoxib. Adjusted for aspirin use and geographic region, ibuprofen users had a 38% higher risk of any major toxicity relative to celecoxib.¹⁴

These trial participants were taking prescription-strength doses for chronic arthritis, so the numbers don’t directly translate to someone popping an occasional 200 mg tablet. Still, the pattern is consistent: celecoxib tends to look better on combined safety endpoints, largely because it is easier on the stomach and kidneys. At over-the-counter doses of 800 to 1,200 mg per day, ibuprofen’s safety profile is comparable to acetaminophen.¹⁵ The risk escalation really kicks in at the higher prescription doses of 1,800 to 2,400 mg per day taken long-term.

Drug Interactions That Matter

Two interactions deserve special attention because they are common and underappreciated among people with arthritis.

The first involves aspirin. Many arthritis patients, especially older ones, also take low-dose aspirin for heart protection. Ibuprofen can block aspirin from accessing the enzyme it needs to inhibit platelet clumping, effectively undermining aspirin’s cardioprotective effect. A study of over 7,000 patients with cardiovascular disease found that those taking both aspirin and ibuprofen had nearly double the risk of all-cause mortality and significantly higher cardiovascular mortality compared with aspirin alone.¹⁶ Laboratory work confirmed the mechanism: coadministration of ibuprofen with aspirin led to a significant rebound in platelet aggregation markers, meaning ibuprofen was physically preventing aspirin from doing its job.¹⁷ If you take daily aspirin and need an NSAID, timing matters: taking aspirin at least 30 minutes before ibuprofen can help, though discussing alternatives with your doctor is the safer bet.

The second interaction is with blood pressure medications. Ibuprofen has been documented to interfere with multiple classes of antihypertensive drugs, including beta-blockers, ACE inhibitors, and diuretics.¹⁸ A double-blind, placebo-controlled trial found that ibuprofen raised supine systolic blood pressure by about 7 mm Hg relative to placebo in patients already being treated for hypertension.¹⁹ A separate study specifically examining patients on ACE inhibitors found that ibuprofen caused significantly greater increases in both systolic and diastolic blood pressure compared to placebo, while celecoxib and nabumetone did not.²⁰ For the roughly half of arthritis patients who also manage high blood pressure, this isn’t a trivial concern.

Reducing the Risks

You don’t have to choose between effective pain relief and stomach damage if you plan ahead. Several strategies can shift the risk-benefit balance.

Gastroprotective co-therapy: Proton pump inhibitors are the first-line comedication and effectively reduce GI adverse events during long-term NSAID use.²¹ A fixed-dose combination tablet of ibuprofen with famotidine (a different class of acid-reducer) reduced the risk of upper GI ulcers by 44% overall and by 55% in patients over 60, compared with ibuprofen alone.²² The challenge with prescribing a separate gastroprotective pill is that people often stop taking it; combination tablets solve this compliance gap.²³
Topical ibuprofen: For arthritis in accessible joints like the knee or hand, topical formulations can deliver the drug locally while keeping blood levels low. A double-blind study comparing 5% ibuprofen gel to oral ibuprofen tablets found similar efficacy for soft tissue injuries, with no significant difference in time to resolution.²⁴ Topical application dramatically reduces systemic exposure, which means less risk to the stomach, kidneys, and heart. For single-joint arthritis in a superficial location, topical NSAIDs are increasingly recommended as a first choice.
Lowest effective dose: The difference in safety between low over-the-counter doses and high prescription doses is substantial, as outlined in the NSAID comparison section above. Starting low and stepping up only if needed is the simplest way to limit risk.

Does Ibuprofen Damage Cartilage Over Time?

This question matters because osteoarthritis is fundamentally a disease of cartilage breakdown, and no one wants a pain reliever that accelerates the problem. The evidence is surprisingly reassuring. A systematic review found that NSAIDs had no harmful effect on healthy, mature cartilage cells, though they did interfere with chondrocyte differentiation and graft incorporation, meaning they could be a problem after cartilage repair surgery or transplantation.²⁵

A study tracking biomarkers of cartilage turnover in osteoarthritis patients undergoing a physical training program found that ibuprofen did not significantly change levels of urinary CTX-II, a marker of cartilage degradation.²⁶ Another trial specifically examining cartilage and synovium biomarkers found that placebo-treated patients showed a significant increase in CTX-II over four to six weeks, while ibuprofen-treated patients showed essentially no change, and the difference between groups was statistically significant.²⁷ That last finding actually suggests ibuprofen may slow cartilage breakdown, possibly by reducing the inflammation that drives it. The caveat is that biomarker changes don’t always translate neatly into long-term clinical outcomes, but at a minimum, the data don’t support the worry that ibuprofen eats away at your cartilage.

Special Concerns for Older Adults

Arthritis is disproportionately a disease of aging, which means the people who need ibuprofen most are also the people most vulnerable to its side effects. Older adults are more likely to have reduced kidney function, to take blood pressure or heart medications, and to have thinner gastrointestinal lining, all of which amplify ibuprofen’s risks.²⁸ The gastroprotective data mentioned earlier showed that the benefit of combining ibuprofen with famotidine was even more pronounced in patients over 60, where the ulcer risk reduction reached 55%.²² That number reflects both the higher baseline risk and the greater absolute benefit of protection. For older adults, regular blood work to monitor kidney function and blood counts is a reasonable precaution during ongoing NSAID therapy.

Why People Respond Differently

You may have noticed that ibuprofen works brilliantly for some people and does almost nothing for others. Part of this comes down to genetics. Ibuprofen is processed in the liver primarily by an enzyme called CYP2C9, and people carry different versions of the gene that codes for it. A systematic review of pharmacogenetic studies found that slow metabolizers of CYP2C9 showed a trend toward greater pain reduction from ibuprofen, presumably because the drug stays active in their system longer, though the effect did not reach statistical significance in the trials examined. In general, the influence of CYP2C9 and CYP2C8 genetic variation on ibuprofen’s painkilling ability appears to be modest at best.²⁹ Genetic testing for NSAID response is not standard practice and likely won’t be anytime soon. But if ibuprofen consistently fails you at reasonable doses, it’s not imaginary. Your liver may simply clear it faster than average, and switching to a different NSAID with a different metabolic pathway is a practical workaround.